ArticleHeart (British Cardiac Society)2007
Human embryonic stem cell transplantation to repair the infarcted myocardium.
Article in Heart (British Cardiac Society), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 208 citations in OpenAlex.
- Spaceflight alters protein levels and gene expression associated with stress response and metabolic characteristics in human cardiac spheroids.Biomaterials · 2025Article
- Vimentin protects differentiating stem cells from stress.Scientific reports · 2020Article
- Optimizing Anisotropic Polyurethane Scaffolds to Mechanically Match with Native Myocardium.ACS biomaterials science & engineering · 2020Article
- Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering.Advanced therapeutics · 2020Article
- Alginate Formulations: Current Developments in the Race for Hydrogel-Based Cardiac Regeneration.Frontiers in bioengineering and biotechnology · 2020Review
- Human embryonic stem cells: Distinct molecular personalities and applications in regenerative medicine.Clinical anatomy (New York, N.Y.) · 2019Review
- The march of pluripotent stem cells in cardiovascular regenerative medicine.Stem cell research & therapy · 2018Review
- RGDfK-Peptide Modified Alginate Scaffold for Cell Transplantation and Cardiac Neovascularization.Tissue engineering. Part A · 2018Article
- Ceramide and S1P Signaling in Embryonic Stem Cell Differentiation.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium.Circulation research · 2017Article
- Rapamycin efficiently promotes cardiac differentiation of mouse embryonic stem cells.Bioscience reports · 2017Article
- Novel surface-enhanced Raman scattering-based assays for ultra-sensitive detection of human pluripotent stem cells.Biomaterials · 2016Article
- Simulated Microgravity and 3D Culture Enhance Induction, Viability, Proliferation and Differentiation of Cardiac Progenitors from Human Pluripotent Stem Cells.Scientific reports · 2016Article
- hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.Journal of cellular and molecular medicine · 2016Review
- Designing Biopolymer Microthreads for Tissue Engineering and Regenerative Medicine.Current stem cell reports · 2016Article
- Non-invasive Chamber-Specific Identification of Cardiomyocytes in Differentiating Pluripotent Stem Cells.Stem cell reports · 2016Article
- Expansion of cardiac progenitors from reprogrammed fibroblasts as potential novel cardiovascular therapy.Stem cell investigation · 2016Article
- Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough?PloS one · 2016Article
- In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin'.Stem cell research & therapy · 2015Review
- Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes, Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for Cardiac Repair.Stem cell reports · 2015Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo test the hypothesis that human embryonic stem cells (hESCs) can be guided to form new myocardium by transplantation into the normal or infarcted heart, and to assess the influence of hESC-derived cardiomyocytes (hESCMs) on cardiac function in a rat model of myocardial infarction (MI).
methodsUndifferentiated hESCs (0.5-1x10(6)), human embryoid bodies (hEBs) (4-8 days; 0.5-1x10(6)), 0.1 mm pieces of embryonic stem-derived beating myocardial tissue, and phosphate-buffered saline (control) were injected into the normal or infarcted myocardium of athymic nude rats (n = 58) by direct injection into the muscle or into preimplanted three-dimensional alginate scaffold. By 2-4 weeks after transplantation, heart sections were examined to detect the human cells and differentiation with fluorescent in situ hybridisation, using DNA probes specific for human sex chromosomes and HLA-DR or HLA-ABC immunostaining.
resultsMicroscopic examination showed transplanted human cells in the normal, and to a lesser extent in the infarcted myocardium (7/7 vs 2/6; p<0.05). The transplanted hESCs and hEBs rarely created new vessels and did not form new myocardium. Transplantation of hESCM tissue into normal heart produced islands of disorganised myofibres, fibrosis and, in a single case, a teratoma. However, transplantation of hESCMs into the infarcted myocardium did prevent post-MI dysfunction and scar thinning.
conclusionsUndifferentiated hESCs and hEBs are not directed to form new myocardium after transplantation into normal or infarcted heart and may create teratoma. Nevertheless, this study shows that hESC-derived cardiomyocyte transplantation can attenuate post-MI scar thinning and left ventricular dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.